AMRX
Amneal Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$4.28B
5Y Perf.+179.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
AMRX vs TEVA
Revenue, margins, valuation, and 5-year total return — side by side.
TEVA
Teva Pharmaceutical Industries Limited
Drug Manufacturers - Specialty & Generic
Market Cap$42.31B
5Y Perf.+190.0%
AMRX vs TEVA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | AMRX | TEVA |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $4.28B | $42.31B |
| Revenue (TTM) | $3.02B | $17.35B |
| Net Income (TTM) | $72M | $1.56B |
| Gross Margin | 36.9% | 52.1% |
| Operating Margin | -0.2% | 13.2% |
| Forward P/E | 13.7x | 14.7x |
| Total Debt | $124M | $17.38B |
| Cash & Equiv. | $282M | $3.56B |
AMRX vs TEVA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AMRX
TEVA
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Amneal Pharmaceutic… (AMRX) | 100 | 279.7 | +179.7% |
| Teva Pharmaceutical… (TEVA) | 100 | 290.0 | +190.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AMRX vs TEVA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TEVA leads in 4 of 7 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Amneal Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and valuation and capital efficiency. As sector peers, any of these can serve as alternatives in the same allocation.
AMRX
Amneal Pharmaceuticals, Inc.
The Growth Play
AMRX is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth 8.0%, EPS growth 157.9%, 3Y rev CAGR 10.9%
- Lower volatility, beta 1.17, Low D/E 12.8%, current ratio 2.17x
- 8.0% revenue growth vs TEVA's 4.3%
Best for: growth exposure and sleep-well-at-night
TEVA
Teva Pharmaceutical Industries Limited
The Income Pick
TEVA carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 1.13
- -24.0% 10Y total return vs AMRX's -54.3%
- Beta 1.13, current ratio 1.04x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AMRX | 8.0% revenue growth vs TEVA's 4.3% |
| Value | AMRX | Lower P/E (13.7x vs 14.7x) |
| Quality / Margins | TEVA | 9.0% margin vs AMRX's 2.4% |
| Stability / Safety | TEVA | Beta 1.13 vs AMRX's 1.17 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | TEVA | +125.4% vs AMRX's +89.7% |
| Efficiency (ROA) | TEVA | 3.9% ROA vs AMRX's 2.0%, ROIC 7.7% vs -0.2% |
AMRX vs TEVA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2025
AMRX vs TEVA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTEVALAGGINGAMRX
AMRXAmneal Pharmaceutical…
1leads
TEVATeva Pharmaceutical I…
5leads
6 Total Categories
CATEGORYLEADERvs AMRXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TEVA4/6
Valuation MetricsMultiples, price ratios, and targets
AMRX4/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TEVA5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
TEVA4/6
Risk & VolatilityBeta, volatility, and downside exposure
TEVA2/2
Analyst OutlookRatings, price targets, and dividends
TEVA1/1
Income & Cash Flow (Last 12 Months)
TEVA leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TEVA is the larger business by revenue, generating $17.3B annually — 5.7x AMRX's $3.0B. TEVA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to AMRX's 2.4%. On growth, AMRX holds the edge at +11.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | AMRXAmneal Pharmaceut… | TEVATeva Pharmaceutic… |
|---|---|---|
| RevenueTrailing 12 months | $3.0B | $17.3B |
| EBITDAEarnings before interest/tax | $169M | $3.3B |
| Net IncomeAfter-tax profit | $72M | $1.6B |
| Free Cash FlowCash after capex | $150M | $1.2B |
| Gross MarginGross profit ÷ Revenue | +36.9% | +52.1% |
| Operating MarginEBIT ÷ Revenue | -0.2% | +13.2% |
| Net MarginNet income ÷ Revenue | +2.4% | +9.0% |
| FCF MarginFCF ÷ Revenue | +5.0% | +6.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +11.5% | +2.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.1% | +72.2% |
TEVA leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
AMRX leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
At 30.3x trailing earnings, TEVA trades at a 51% valuation discount to AMRX's 61.9x P/E.
| Metric | AMRXAmneal Pharmaceut… | TEVATeva Pharmaceutic… |
|---|---|---|
| Market CapShares × price | $4.3B | $42.3B |
| Enterprise ValueMkt cap + debt − cash | $4.1B | $56.1B |
| Trailing P/EPrice ÷ TTM EPS | 61.91x | 30.28x |
| Forward P/EPrice ÷ next-FY EPS est. | 13.71x | 14.68x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 17.77x |
| Price / SalesMarket cap ÷ Revenue | 1.42x | 2.45x |
| Price / BookPrice ÷ Book value/share | 4.58x | 5.39x |
| Price / FCFMarket cap ÷ FCF | 15.86x | 36.85x |
AMRX leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
TEVA leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
TEVA delivers a 20.7% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $7 for AMRX. AMRX carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to TEVA's 2.20x.
| Metric | AMRXAmneal Pharmaceut… | TEVATeva Pharmaceutic… |
|---|---|---|
| ROE (TTM)Return on equity | +7.5% | +20.7% |
| ROA (TTM)Return on assets | +2.0% | +3.9% |
| ROICReturn on invested capital | -0.2% | +7.7% |
| ROCEReturn on capital employed | -0.2% | +8.0% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 8 |
| Debt / EquityFinancial leverage | 0.13x | 2.20x |
| Net DebtTotal debt minus cash | -$158M | $13.8B |
| Cash & Equiv.Liquid assets | $282M | $3.6B |
| Total DebtShort + long-term debt | $124M | $17.4B |
| Interest CoverageEBIT ÷ Interest expense | 2.09x | 2.51x |
TEVA leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
TEVA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TEVA five years ago would be worth $35,311 today (with dividends reinvested), compared to $23,564 for AMRX. Over the past 12 months, TEVA leads with a +125.4% total return vs AMRX's +89.7%. The 3-year compound annual growth rate (CAGR) favors AMRX at 88.9% vs TEVA's 58.9% — a key indicator of consistent wealth creation.
| Metric | AMRXAmneal Pharmaceut… | TEVATeva Pharmaceutic… |
|---|---|---|
| YTD ReturnYear-to-date | +7.6% | +17.4% |
| 1-Year ReturnPast 12 months | +89.7% | +125.4% |
| 3-Year ReturnCumulative with dividends | +574.3% | +301.0% |
| 5-Year ReturnCumulative with dividends | +135.6% | +253.1% |
| 10-Year ReturnCumulative with dividends | -54.3% | -24.0% |
| CAGR (3Y)Annualised 3-year return | +88.9% | +58.9% |
TEVA leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
TEVA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TEVA is the less volatile stock with a 1.13 beta — it tends to amplify market swings less than AMRX's 1.17 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TEVA currently trades 97.3% from its 52-week high vs AMRX's 89.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AMRXAmneal Pharmaceut… | TEVATeva Pharmaceutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.17x | 1.13x |
| 52-Week HighHighest price in past year | $15.20 | $37.35 |
| 52-Week LowLowest price in past year | $7.02 | $14.99 |
| % of 52W HighCurrent price vs 52-week peak | +89.6% | +97.3% |
| RSI (14)Momentum oscillator 0–100 | 59.9 | 71.9 |
| Avg Volume (50D)Average daily shares traded | 1.7M | 6.5M |
TEVA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
TEVA leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates AMRX as "Buy" and TEVA as "Buy". Consensus price targets imply 24.8% upside for AMRX (target: $17) vs 7.3% for TEVA (target: $39).
| Metric | AMRXAmneal Pharmaceut… | TEVATeva Pharmaceutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $17.00 | $39.00 |
| # AnalystsCovering analysts | 16 | 46 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
TEVA leads this category, winning 1 of 1 comparable metric.
Key Takeaway
TEVA leads in 5 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AMRX leads in 1 (Valuation Metrics).
Best OverallTeva Pharmaceutical Industr… (TEVA)Leads 5 of 6 categories
Loading custom metrics...
AMRX vs TEVA: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is AMRX or TEVA a better buy right now?
For growth investors, Amneal Pharmaceuticals, Inc.
(AMRX) is the stronger pick with 8. 0% revenue growth year-over-year, versus 4. 3% for Teva Pharmaceutical Industries Limited (TEVA). Teva Pharmaceutical Industries Limited (TEVA) offers the better valuation at 30. 3x trailing P/E (14. 7x forward), making it the more compelling value choice. Analysts rate Amneal Pharmaceuticals, Inc. (AMRX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AMRX or TEVA?
On trailing P/E, Teva Pharmaceutical Industries Limited (TEVA) is the cheapest at 30.
3x versus Amneal Pharmaceuticals, Inc. at 61. 9x. On forward P/E, Amneal Pharmaceuticals, Inc. is actually cheaper at 13. 7x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — AMRX or TEVA?
Over the past 5 years, Teva Pharmaceutical Industries Limited (TEVA) delivered a total return of +253.
1%, compared to +135. 6% for Amneal Pharmaceuticals, Inc. (AMRX). Over 10 years, the gap is even starker: TEVA returned -24. 0% versus AMRX's -54. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AMRX or TEVA?
By beta (market sensitivity over 5 years), Teva Pharmaceutical Industries Limited (TEVA) is the lower-risk stock at 1.
13β versus Amneal Pharmaceuticals, Inc. 's 1. 17β — meaning AMRX is approximately 4% more volatile than TEVA relative to the S&P 500. On balance sheet safety, Amneal Pharmaceuticals, Inc. (AMRX) carries a lower debt/equity ratio of 13% versus 2% for Teva Pharmaceutical Industries Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — AMRX or TEVA?
By revenue growth (latest reported year), Amneal Pharmaceuticals, Inc.
(AMRX) is pulling ahead at 8. 0% versus 4. 3% for Teva Pharmaceutical Industries Limited (TEVA). On earnings-per-share growth, the picture is similar: Teva Pharmaceutical Industries Limited grew EPS 182. 8% year-over-year, compared to 157. 9% for Amneal Pharmaceuticals, Inc.. Over a 3-year CAGR, AMRX leads at 10. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AMRX or TEVA?
Teva Pharmaceutical Industries Limited (TEVA) is the more profitable company, earning 8.
2% net margin versus 2. 4% for Amneal Pharmaceuticals, Inc. — meaning it keeps 8. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TEVA leads at 12. 5% versus -0. 2% for AMRX. At the gross margin level — before operating expenses — TEVA leads at 51. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AMRX or TEVA more undervalued right now?
On forward earnings alone, Amneal Pharmaceuticals, Inc.
(AMRX) trades at 13. 7x forward P/E versus 14. 7x for Teva Pharmaceutical Industries Limited — 1. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AMRX: 24. 8% to $17. 00.
08Which pays a better dividend — AMRX or TEVA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is AMRX or TEVA better for a retirement portfolio?
For long-horizon retirement investors, Teva Pharmaceutical Industries Limited (TEVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
13)). Both have compounded well over 10 years (TEVA: -24. 0%, AMRX: -54. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AMRX and TEVA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(AMRX: 11.5% · TEVA: 2.3%)Net Margin>
%
(AMRX: 2.4% · TEVA: 9.0%)P/E Ratio<
x
(AMRX: 61.9x · TEVA: 30.3x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.